Clinical Roundup Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows April 12, 2024Vol.50 No.15
Clinical Roundup One in five people with cancer participate in medical research studies, Fred Hutchinson study shows April 05, 2024Vol.50 No.14
Clinical Roundup Phase II study of personalized cancer vaccine in CRC shows positive preliminary PFS and long-term ctDNA data April 05, 2024Vol.50 No.14
Clinical Roundup Study finds TNBC tumors with an increase in immune cells have lower risk of recurrence after surgery April 05, 2024Vol.50 No.14
Clinical Roundup Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study April 05, 2024Vol.50 No.14
Clinical Roundup UTSW discovers protective ‘acid wall’ formed by cancer cells April 05, 2024Vol.50 No.14
Clinical Roundup Phase III Opdivo + Yervoy trial meets primary endpoint in advanced HCC March 29, 2024Vol.50 No.13
Clinical Roundup UCLA: Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence March 29, 2024Vol.50 No.13
Clinical Roundup Imfinzi regimen reduces the risk of disease progression or death in liver cancer eligible for embolization March 29, 2024Vol.50 No.13
Clinical Roundup Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test March 29, 2024Vol.50 No.13
